Affordability of Oral HCV Treatments
Robert Hindes, MD, a leader in pharmaceutical development and business, serves as the chief medical officer of Trek Therapeutics. In this position, Robert Hindes, MD, currently works to create innovative, affordable, and accessible medicines to treat hepatitis C virus (HCV) infections around the world.

Trek Therapeutics elected to focus on HCV treatments because chronic HCV infection has become a global epidemic that presently affects an estimated 130 to 170 million people worldwide from a variety of economic backgrounds. As the most prevalent cause of advanced liver disease in the United States, HCV infection contributes to approximately 25 percent of the cases of liver cirrhosis, 25 to 30 percent of primary liver cancer cases, and 350,000 HCV-related deaths every year.

According to Trek Therapeutics, recently approved and extremely effective oral drug combinations have been helping to cure many people with HCV across the U.S., Japan, and Europe. For patients with limited access to funds or medical insurance, however, the high-priced drug combinations are not affordable and the treatable HCV infections continue to have a devastating impact.

Trek Therapeutics plans to launch its more affordable HCV combo treatments in Egypt, the U.S., Europe, China, and Southeast Asia between 2017 and 2022.                            
Affordability of Oral HCV Treatments
0
49
0
Published:

Affordability of Oral HCV Treatments

Robert Hindes, MD, a leader in pharmaceutical development and business, serves as the chief medical officer of Trek Therapeutics. In this positio Read More
0
49
0
Published:

Creative Fields